UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 212

Sortiert nach

Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial

Journal of clinical oncology, 2016-04, Vol.34 (10), p.1034-1042

2016

Link zum Volltext

Verfügbarkeit prüfen

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response

The lancet oncology, 2014-09, Vol.15 (10), p.1137-1146

2014

Link zum Volltext

Verfügbarkeit prüfen

Effect of Age on Breast Cancer Outcomes in Women With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Results From a Herceptin Adjuvant Trial

Journal of clinical oncology, 2013-07, Vol.31 (21), p.2692-2698

2013

Link zum Volltext

Verfügbarkeit prüfen

Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D)

European journal of cancer (1990), 2021-05, Vol.148, p.287-296

2021

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of Severe Infection and Survival After Splenectomy

The American journal of medicine, 2006-03, Vol.119 (3), p.276.e1-276.e7

2006

Link zum Volltext

Verfügbarkeit prüfen

Difficulties arising in reimbursement recommendations on new medicines due to inadequate reporting of population adjustment indirect comparison methods

Research synthesis methods, 2019-12, Vol.10 (4), p.615-617

2019

Link zum Volltext

Verfügbarkeit prüfen

Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials

NPJ breast cancer, 2022-05, Vol.8 (1), p.68-68, Article 68

2022

Link zum Volltext

Verfügbarkeit prüfen

Acquired transverse myelopathy in children in the United Kingdom – A 2 year prospective study

European journal of paediatric neurology, 2010-11, Vol.14 (6), p.479-487

2010

Link zum Volltext

Verfügbarkeit prüfen

Patient-based evidence: its role in decision making on end-of-life, orphan, and ultra-orphan medicines

International journal of technology assessment in health care, 2023-04, Vol.39 (1), p.e19-e19, Article e19

2023

Link zum Volltext

Verfügbarkeit prüfen

OP242 Patient-based Evidence: A Comparison Of The Views Of Patient And Clinical Engagement Participants And Committee Members

International journal of technology assessment in health care, 2021-12, Vol.37 (S1), p.8-8

2021

Link zum Volltext

Verfügbarkeit prüfen

PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer

Journal of clinical oncology, 2015-04, Vol.33 (12), p.1334-1339

2015

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors ≤ 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials

Journal of clinical oncology, 2015-08, Vol.33 (24), p.2600-2608

2015

Link zum Volltext

Verfügbarkeit prüfen

OP22 Patient-Based Evidence: Its Role In Decision-Making On New Medicines

International journal of technology assessment in health care, 2019, Vol.35 (S1), p.4-5

2019

Link zum Volltext

Verfügbarkeit prüfen

Maturity and medical students' ease of transition into the clinical environment

Medical teacher, 2009-01, Vol.31 (7), p.621-626

2009

Link zum Volltext

Verfügbarkeit prüfen

Influenza and pneumococcal vaccination in Scottish nursing homes: coverage, policies and reasons for receipt and non-receipt of vaccine

Vaccine, 2002-06, Vol.20 (19), p.2516-2522

2002

Link zum Volltext

Verfügbarkeit prüfen

Regional Nodal Irradiation After Breast Conserving Surgery for Early HER2-Positive Breast Cancer: Results of a Subanalysis From the ALTTO Trial

JNCI : Journal of the National Cancer Institute, 2017-08, Vol.109 (8)

2017

Link zum Volltext

Verfügbarkeit prüfen

Reply to A. Oguz et al

Journal of clinical oncology, 2016-02, Vol.34 (6), p.640-641

2016

Link zum Volltext

Verfügbarkeit prüfen

Association between adaptive immune signature and outcome in HER2-positive breast cancer treated with trastuzumab and lapatinib in the NCCTG-N9831 (Alliance) and NeoALTTO trials

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.577-577

2018

Link zum Volltext

Verfügbarkeit prüfen

Regional nodal irradiation after breast conserving surgery for HER2-positive breast cancer: Results of a sub analysis from the ALTTO trial

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.604-604

2016

Link zum Volltext

Verfügbarkeit prüfen

Survival outcomes of the NeoALTTO study: Updated results of a randomized multicenter phase III neoadjuvant trial

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.512-512

2017

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of adjuvant trastuzumab (T) compared with no T for patients (pts) with HER2-positive breast cancer and tumors ≤ 2cm: A meta-analysis of the randomized trastuzumab trials

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.508-508

2014

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 212

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(181)
Mit Volltextzugriff
(170)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response

CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01)

Effect of Age on Breast Cancer Outcomes in Women With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Results From a Herceptin Adjuvant Trial

Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D)

Evaluation of Severe Infection and Survival After Splenectomy

Difficulties arising in reimbursement recommendations on new medicines due to inadequate reporting of population adjustment indirect comparison methods

Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials

Acquired transverse myelopathy in children in the United Kingdom – A 2 year prospective study

Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial

Patient-based evidence: its role in decision making on end-of-life, orphan, and ultra-orphan medicines

OP242 Patient-based Evidence: A Comparison Of The Views Of Patient And Clinical Engagement Participants And Committee Members

PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer

Survival outcomes of the NeoALTTO study (BIG 1–06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer

Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors ≤ 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials

OP22 Patient-Based Evidence: Its Role In Decision-Making On New Medicines

Maturity and medical students' ease of transition into the clinical environment

Influenza and pneumococcal vaccination in Scottish nursing homes: coverage, policies and reasons for receipt and non-receipt of vaccine

Regional Nodal Irradiation After Breast Conserving Surgery for Early HER2-Positive Breast Cancer: Results of a Subanalysis From the ALTTO Trial

Reply to A. Oguz et al

Association between adaptive immune signature and outcome in HER2-positive breast cancer treated with trastuzumab and lapatinib in the NCCTG-N9831 (Alliance) and NeoALTTO trials

Regional nodal irradiation after breast conserving surgery for HER2-positive breast cancer: Results of a sub analysis from the ALTTO trial

Survival outcomes of the NeoALTTO study: Updated results of a randomized multicenter phase III neoadjuvant trial

Updated results from the phase III ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L) or their combination (L+T) in the adjuvant treatment of HER2-positive early breast cancer

Efficacy of adjuvant trastuzumab (T) compared with no T for patients (pts) with HER2-positive breast cancer and tumors ≤ 2cm: A meta-analysis of the randomized trastuzumab trials

Suchergebnisse filtern